Insmed Inc (INSM)vsOcugen Inc (OCGN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
OCGN
Ocugen Inc
$1.95
+1.56%
HEALTHCARE · Cap: $688.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 13642% more annual revenue ($606.42M vs $4.41M). OCGN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
OCGN
Hold36
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 85.6%
Revenue surging 54.2% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -7.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : OCGN
The strongest argument for OCGN centers on Operating Margin, Revenue Growth. Revenue growth of 54.2% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : OCGN
The primary concerns for OCGN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while OCGN is a hypergrowth play — different risk/reward profiles.
OCGN carries more volatility with a beta of 2.90 — expect wider price swings.
OCGN is growing revenue faster at 54.2% — sustainability is the question.
OCGN generates stronger free cash flow (-14M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Ocugen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?